Orforglipron Half-Life: How Long It Stays in Your System

Orforglipron at a glance:

• Drug class: Oral non-peptide GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• Route: oral tablet
• Typical frequency: once daily, no fasting required
• Half-life: approximately 24-48 hours
• Receptor target: GLP-1 receptor

The half-life of Orforglipron (approximately 24-48 hours) is the single most important number for understanding why it's dosed the way it is. Below we unpack the practical implications.

Half-Life Defined

The half-life is the time it takes for the concentration of a drug in the bloodstream to fall by half. It governs how often a drug needs to be dosed to maintain therapeutic levels and how long the drug persists after the last dose.

For Orforglipron, the half-life is approximately 24-48 hours. That number explains the once daily, no fasting required dosing schedule.

Time to Steady State

After starting (or changing) a dose, drug levels reach a new "steady state" after about 5 half-lives.

For Orforglipron: with a 5-7 day half-life, steady state at a new dose is reached around 4-5 weeks. That's why dose increases are spaced ~4 weeks apart in the standard titration schedule.

How Long Orforglipron Stays in Your System

A common question: "if I stop Orforglipron, how long does it stay in my body?"

The standard rule of thumb is that a drug is essentially cleared after 5 half-lives. For Orforglipron: that's approximately 240 hours. Effects on appetite, glucose, or other targets persist for a similar period before fully resolving.

For incretin agents specifically, the appetite-related effects fade over weeks after stopping.

Practical Implications

A long half-life:

• Allows less frequent dosing (better adherence)
• Smooths out peaks and troughs (often better tolerability)
• Means dose changes take longer to fully express
• Creates a longer "runway" if a dose is missed

A short half-life:

• Requires more frequent dosing
• Produces sharper concentration peaks (and matching side effects)
• Allows faster dose adjustments
• Provides faster clearance if stopped

Orforglipron, with its short half-life, falls on the short end of this spectrum.

Half-Life and Missed Doses

If a dose is missed:

• Take the missed dose as soon as you remember if you're well within the dosing interval
• Skip it if you're closer to the next dose
• Never double up

The longer the half-life, the more forgiving the missed-dose window. For Orforglipron, timing matters more.

Half-Life Across the Drug Class

Within the broader class of oral non-peptide glp-1 receptor agonist, half-lives vary significantly. Daily agents (liraglutide) have shorter half-lives; weekly agents (semaglutide, dulaglutide, tirzepatide) have half-lives in the multi-day range. See our comparison pages for direct comparisons.

Bottom Line

The approximately 24-48 hours half-life of Orforglipron is what makes its once daily, no fasting required schedule work. Shorter half-lives need more frequent dosing; longer ones offer more flexibility.

Frequently Asked Questions

Related Reading

• The Honest Guide to Orforglipron: What Patients and Doctors Actually Say
• Orforglipron Side Effects: 7 Things to Watch For (and How to Manage Them)
• Orforglipron Results: What the Real Numbers Show in 2026
• Orforglipron Cost Explained: Monthly, Yearly, and How to Save
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.
• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.

This page is informational only and is not medical advice.